Eli Lilly And Co vs Advanced Drainage Systems Inc — how do they compare? Eli Lilly And Co trades at $1,225.18 (market cap $1.08T), while Advanced Drainage Systems Inc trades at $139.02 (market cap $10.83B). The key difference: Eli Lilly And Co is far larger — about 99.7× Advanced Drainage Systems Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | WMS | |
|---|---|---|
Market Cap | $1.08T | $10.83B |
Sector | Health | Industrials |
52-Week High | $1.24K | $175.38 |
52-Week Low | $639.43 | $129.50 |
Enterprise Value | $1.13T | $12.44B |
Dividend Yield | 0.57% | 0.56% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Advanced Drainage Systems (WMS) trades at $141.67, down 1.58% with bearish technical signals. The company demonstrates strong profitability with 14% net margins and consistent earnings beats, though revenue growth has moderated. Recent Q1 2027 results showed 21% sales growth to $1 billion, beating expectations. Technical indicators show resistance at $143 with support at $140, while moving averages signal bearish momentum.
WMS offers solid fundamentals with attractive upside to the $185.86 consensus target, but faces near-term technical headwinds. The company's water management solutions benefit from infrastructure spending, though competitive pressures and margin compression present risks. Analyst sentiment is mixed with 41% buy ratings, suggesting cautious optimism for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →